Ratings Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris Other stock markets 11:35:08 2024-04-25 am EDT			5-day change	1st Jan Change
14.74 ^EUR	-2.38%		+4.39%	+50.10%

Apr. 11	Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	MT
Apr. 08	Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABIVAX	+50.10%	1.02B	-
IQVIA HOLDINGS INC.	+1.12%	43.84B	B
MODERNA, INC.	+6.77%	41.68B	B-
LONZA GROUP AG	+45.26%	41.25B	A
CELLTRION, INC.	-11.96%	27.04B	C
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B	C+
MEDPACE HOLDINGS, INC.	+27.16%	12.29B	C+
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes